KRN125(pegfilgrastim), PLR001(plerixafor) + KRN8601(filgrastim), PLR001(plerixafor)
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Multiple Myeloma and Malignant Lymphoma
Conditions
Multiple Myeloma and Malignant Lymphoma
Trial Timeline
Sep 1, 2021 → Oct 25, 2022
NCT ID
NCT05007652About KRN125(pegfilgrastim), PLR001(plerixafor) + KRN8601(filgrastim), PLR001(plerixafor)
KRN125(pegfilgrastim), PLR001(plerixafor) + KRN8601(filgrastim), PLR001(plerixafor) is a phase 2 stage product being developed by Kyowa Kirin for Multiple Myeloma and Malignant Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT05007652. Target conditions include Multiple Myeloma and Malignant Lymphoma.
What happened to similar drugs?
20 of 20 similar drugs in Multiple Myeloma and Malignant Lymphoma were approved
Approved (20) Terminated (0) Active (0)
✅Solifenacin Succinate + Solifenacin Succinate + Oxybutynin Hydrochloride + PlaceboAstellas PharmaApproved
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05007652 | Phase 2 | Completed |
Competing Products
20 competing products in Multiple Myeloma and Malignant Lymphoma